Stock surges on data: Social media chatter has intensified around Legend Biotech following reports of strong off-the-shelf in vivo CAR-T results that propelled shares sharply higher in recent sessions.
Acquisition speculation: Observers note potential interest from larger players such as Johnson & Johnson in the company's expanding platform, with some highlighting opportunities to extend the technology beyond oncology into autoimmune indications.
Manufacturing context: Discussions also touch on broader regulatory challenges in cell therapy production, where the company's existing approved therapy could benefit from new modalities that reduce failure rates.
Note: This discussion summary was generated from an AI condensation of post data.
Legend Biotech Insider Trading Activity
Legend Biotech insiders have traded $LEGN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $LEGN stock by insiders over the last 6 months:
- YING HUANG (Chief Executive Officer) sold 9,936 shares for an estimated $87,138
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Legend Biotech Hedge Fund Activity
We have seen 115 institutional investors add shares of Legend Biotech stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,969,662 shares (+100.2%) to their portfolio in Q4 2025, for an estimated $64,560,451
- FIRST BEIJING INVESTMENT LTD added 2,296,335 shares (+inf%) to their portfolio in Q1 2026, for an estimated $41,540,700
- JANUS HENDERSON GROUP PLC removed 2,125,085 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $46,199,347
- KYNAM CAPITAL MANAGEMENT, LP added 1,576,295 shares (+inf%) to their portfolio in Q1 2026, for an estimated $28,515,176
- ALLIANCEBERNSTEIN L.P. removed 1,517,067 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $27,443,742
- FMR LLC added 1,428,517 shares (+5.9%) to their portfolio in Q1 2026, for an estimated $25,841,872
- TWO SIGMA INVESTMENTS, LP added 1,364,326 shares (+259.3%) to their portfolio in Q1 2026, for an estimated $24,680,657
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Legend Biotech Analyst Ratings
Wall Street analysts have issued reports on $LEGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 01/20/2026
To track analyst ratings and price targets for Legend Biotech, check out Quiver Quantitative's $LEGN forecast page.
Legend Biotech Price Targets
Multiple analysts have issued price targets for $LEGN recently. We have seen 8 analysts offer price targets for $LEGN in the last 6 months, with a median target of $64.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $65.0 on 06/03/2026
- Ashwani Verma from UBS set a target price of $49.0 on 06/03/2026
- Leonid Timashev from RBC Capital set a target price of $64.0 on 05/13/2026
- Yaron Werber from TD Cowen set a target price of $29.0 on 05/13/2026
- Matthew Harrison from Morgan Stanley set a target price of $48.0 on 05/13/2026
- Gena Wang from Barclays set a target price of $80.0 on 02/04/2026
- Trevor Allred from Oppenheimer set a target price of $75.0 on 01/07/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
